This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB) “You have to stop treating psoriasis as just a skin disease”. In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that…
View Post 7 min Partner Content Rheumatology RX Digital tools as support for predict-to-treat? In contrast to other therapeutic areas, it is still difficult to achieve remission in all patients in rheumatology. Two applications can increase the chance of clinical remission through joint decision-making…
View Post 7 min This content is machine translated Annual Meeting of the Swiss Society of Rheumatology (SGR Congress) The treatment landscape for chronic inflammatory rheumatic diseases offers scope for individual treatment decisions With the ongoing expansion of the therapeutic landscape, treatment management for chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) is also changing.…
View Post 7 min This content is machine translated Medicalonline Long-term data on upadacitinib show a consistent safety profile and no new safety signals [1]. * With the exception of the already known higher herpes zoster and NMSC events and higher CPK levels.
View Post 1 min This content is machine translated Podcast JAK inhibitors in inflammatory rheumatic diseases. Thanks to the development of advanced therapies, the goal of remission is within reach for more and more patients with inflammatory rheumatic diseases [1]. In the following podcast, Prof. Stephan…
View Post 6 min This content is machine translated Case presentation by Ioannis Papadopoulos, MD. RA patient with severe polyarthritis on JAK inhibitor in remission for more than one year Rheumatoid arthritis (RA) is associated with a high level of suffering for those affected and, if left untreated, can lead to disability. Below, Ioannis Papadopoulos, MD, presents a case in…
View Post 5 min This content is machine translated Interview with Natalie Marcoli, MD “Personalized treatment in rheumatology would help even more patients achieve remission.” Achieving remission is the ultimate goal in the treatment of the inflammatory rheumatic diseases rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis [1-3]. In the following interview, Natalie Marcoli, MD, from…
View Post 8 min This content is machine translated Inflammatory rheumatic diseases Current data and expert opinions on the therapeutic goal of remission The management of inflammatory rheumatic diseases has improved significantly in recent years with the development of targeted treatments [1]. But how realistic is achieving remission today? The following report provides…
View Post 9 min This content is machine translated Interview with Prof. Dr. med. Gerd Burmester “With the JAK inhibitors, we can get much more out of them for our patients” Oral Janus kinase inhibitors (JAKi) have been expanding the treatment landscape for inflammatory rheumatoid diseases for several years. In the following interview, Prof. Dr. med. Gerd Burmester explains what this…
View Post 4 min This content is machine translated Interactive expert Q&A session at the SGR Congress 2022 What you always wanted to know about JAK inhibitors Oral Janus kinase inhibitors (JAKi) are gaining ground in the treatment of inflammatory rheumatoid diseases and were therefore a hotly debated topic at this year’s annual congress of the Swiss…
View Post 11 min This content is machine translated Interview on World Rheumatism Day “When those affected forget about the disease in their daily lives, it’s a particularly nice moment for us physicians.” Every year on October 12 is World Rheumatism Day. This was launched in 1996 by the international federation of self-help associations of rheumatism sufferers, “Arthritis and Rheumatism International (ARI)”. When…
